Cover Image
市場調查報告書

Viamet Pharmaceuticals, Inc.:產品平台分析

Viamet Pharmaceuticals, Inc. - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 253741
出版日期 內容資訊 英文 33 Pages
訂單完成後即時交付
價格
Back to Top
Viamet Pharmaceuticals, Inc.:產品平台分析 Viamet Pharmaceuticals, Inc. - Product Pipeline Review - 2016
出版日期: 2016年04月27日 內容資訊: 英文 33 Pages
簡介

Viamet Pharmaceuticals, Inc.是Viamet Pharmaceuticals Holdings, LLC的子公司,是致力於劃時代抗真菌藥物之開發與商品化的生物製藥公司。該公司基於獨家的金屬酵素醫藥品化學平台"Metallophile" 技術,正在設計具有選擇性且高效力、副作用少的藥劑。

本報告提供Viamet Pharmaceuticals, Inc.的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估等相關資訊。

Viamet Pharmaceuticals, Inc.的基本資料

  • Viamet Pharmaceuticals, Inc.概要
  • 主要資訊
  • 企業資料

Viamet Pharmaceuticals, Inc.:R&D概要

  • 主要的治療範圍

Viamet Pharmaceuticals, Inc.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Viamet Pharmaceuticals, Inc.:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第Ⅱ相的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

Viamet Pharmaceuticals, Inc.:藥物簡介

Viamet Pharmaceuticals, Inc.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Viamet Pharmaceuticals, Inc.:最近的開發平台趨勢

Viamet Pharmaceuticals, Inc.:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08039CDB

Summary

Global Markets Direct's, 'Viamet Pharmaceuticals, Inc. - Product Pipeline Review - 2016', provides an overview of the Viamet Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Viamet Pharmaceuticals, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Viamet Pharmaceuticals, Inc.
  • The report provides overview of Viamet Pharmaceuticals, Inc. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Viamet Pharmaceuticals, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Viamet Pharmaceuticals, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Viamet Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Viamet Pharmaceuticals, Inc.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Viamet Pharmaceuticals, Inc.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Viamet Pharmaceuticals, Inc. Snapshot
    • Viamet Pharmaceuticals, Inc. Overview
    • Key Information
    • Key Facts
  • Viamet Pharmaceuticals, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Viamet Pharmaceuticals, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Viamet Pharmaceuticals, Inc. - Pipeline Products Glance
    • Viamet Pharmaceuticals, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Viamet Pharmaceuticals, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Viamet Pharmaceuticals, Inc. - Drug Profiles
    • VT-1161
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VT-1129
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Orphan Diseases
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VT-1598
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VT-1607
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VT-1654
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VT-1658
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VT-1669
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VT-1681
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Viamet Pharmaceuticals, Inc. - Pipeline Analysis
    • Viamet Pharmaceuticals, Inc. - Pipeline Products by Target
    • Viamet Pharmaceuticals, Inc. - Pipeline Products by Route of Administration
    • Viamet Pharmaceuticals, Inc. - Pipeline Products by Molecule Type
    • Viamet Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action
  • Viamet Pharmaceuticals, Inc. - Recent Pipeline Updates
  • Viamet Pharmaceuticals, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Viamet Pharmaceuticals, Inc., Key Information
  • Viamet Pharmaceuticals, Inc., Key Facts
  • Viamet Pharmaceuticals, Inc. - Pipeline by Indication, 2016
  • Viamet Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016
  • Viamet Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016
  • Viamet Pharmaceuticals, Inc. - Phase II, 2016
  • Viamet Pharmaceuticals, Inc. - Phase I, 2016
  • Viamet Pharmaceuticals, Inc. - Preclinical, 2016
  • Viamet Pharmaceuticals, Inc. - Pipeline by Target, 2016
  • Viamet Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2016
  • Viamet Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2016
  • Viamet Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2016
  • Viamet Pharmaceuticals, Inc. - Recent Pipeline Updates, 2016

List of Figures

  • Viamet Pharmaceuticals, Inc. - Pipeline by Indication, 2016
  • Viamet Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016
  • Viamet Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016
  • Viamet Pharmaceuticals, Inc. - Pipeline by Target, 2016
  • Viamet Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2016
  • Viamet Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2016
  • Viamet Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2016
Back to Top